3Q PREVIEW: GSK, Lilly, BMS, Biogen and Celgene
This article was originally published in Scrip
While the M&A train continued to come off the rails, the big pharma earnings season kicked off on 14 October with Johnson & Johnson reporting stronger than expected results thanks to brisk sales of its HCV shooting star Olysio (simeprevir) (scripintelligence.com, 15 October 2014), followed by Roche revealing upbeat sales as its breast cancer franchise performed well (scripintelligence.com, 16 October).
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.